Profits recover at Alibaba Health but prognosis unclear
The digital pharmacy and healthcare provider returned to profit in the last fiscal year but is still struggling to limit its reliance on drug sales Key Takeaways: Alibaba Health delivered…
0241.HK
Recent Articles
RELATED ARTICLES
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
- HealthyWay seeks Hong Kong IPO to staunch flow of red ink
-
Third time’s the charm: Fangzhou finally finds winning tonic for Hong Kong IPO
6086.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
- Tong Ren Tang Healthcare IPO banks on famous name, growth through M&A
Discover hidden China stock gems in our weekly newsletter